Fulcrum Therapeutics Inc

NASDAQ:FULC 4:00:00 PM EDT

7.28

-0.16 (-2.15%)

6:25:47 PM EDT: $7.64 +0.36 (+4.95%)

Market Cap (Intraday)	450.89M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.42 Million
Adjusted EPS	-$0.44

See more estimates

10-Day MA	$7.47
50-Day MA	$9.39
200-Day MA	$6.13

See more pivots

Fulcrum Therapeutics Inc Stock, NASDAQ:FULC

26 Landsdowne Street, Cambridge, Massachusetts 02139

United States of America

Phone: +1.617.651.8851

Number of Employees: 76

http://www.fulcrumtx.com

Description

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.